Drug Search Results
More Filters [+]

Edotecarin

Alternative Names: edotecarin, J-107088
Latest Update: 2013-12-19
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: TOP1 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Edotecarin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Glioblastoma

Phase 2: Breast Cancer|Gastrointestinal Cancer

Phase 1: Esophageal Cancer|Gastrointestinal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

EDOABC-4439-001

P2

Completed

Breast Cancer

2007-06-01

CDR0000329917

P2

Completed

Breast Cancer

2006-04-01

CDR0000339607

P1

Completed

Gastrointestinal Cancer|Esophageal Cancer

2005-12-01

EDOAGA-6736-001

P2

Completed

Gastrointestinal Cancer

2005-06-01

Recent News Events

Date

Type

Title